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Abstract
Background
DNA methylation is affected by the activities of the key enzymes and intermediate metabo-
lites of the one-carbon pathway, one of which involves homocysteine. We investigated the
effect of the well-known genetic variant associated with mildly elevated homocysteine:
MTHFR 677C>T independently and in combination with other homocysteine-associated
variants, on genome-wide leukocyte DNA-methylation.
Methods
Methylation levels were assessed using Illumina 450k arrays on 9,894 individuals of Euro-
pean ancestry from 12 cohort studies. Linear-mixed-models were used to study the associa-
tion of additive MTHFR 677C>T and genetic-risk score (GRS) based on 18 homocysteine-
associated SNPs, with genome-wide methylation.
Results
Meta-analysis revealed that the MTHFR 677C>T variant was associated with 35 CpG sites
in cis, and the GRS showed association with 113 CpG sites near the homocysteine-associ-
ated variants. Genome-wide analysis revealed that the MTHFR 677C>T variant was associ-
ated with 1 trans-CpG (nearest gene ZNF184), while the GRS model showed association
with 5 significant trans-CpGs annotated to nearest genes PTF1A, MRPL55, CTDSP2,
CRYM and FKBP5.
Conclusions
Our results do not show widespread changes in DNA-methylation across the genome, and
therefore do not support the hypothesis that mildly elevated homocysteine is associated
with widespread methylation changes in leukocytes.
Introduction
DNA methylation, an important epigenetic mechanism has gained interest in the field of can-
cer and aging over the last decade [1, 2]. DNA methylation is affected by the activities of the
key enzymes and intermediate metabolites of the one-carbon pathway, one of which involves
homocysteine (Hcy).
Our aim was to investigate the role of genetically defined Hcy levels on genome-wide DNA
methylation. A number of earlier studies have reported a link between Hcy and DNA methyla-
tion [3]. In these studies, DNA methylation was quantified as a global measure, that represents
the total methyl cytosine content of the DNA. In animal models, both diet- and genetically-
induced elevated Hcy have been related to altered global methylation patterns in tissues of
aorta, brain, liver and colon. In human subjects, global DNA methylation in blood was not
consistently altered with elevated Hcy. The relationship between Hcy and methylation can be
subject to substantial bias, given the strong relationship between several lifestyle factors, dis-
eases and Hcy. A way to circumvent this bias is to use genetic factors determining Hcy concen-
trations as an instrument to study the relationship between Hcy and methylation. The use of
Homocysteine-associated variants and DNA methylation
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number EGAS00001000910. The informed
consents given by KORA study participants do not
cover data posting in public databases. However,
data are available upon request from KORA-gen
(https://epi.helmholtz-muenchen.de/). Data
requests can be submitted online and are subject
to approval by the KORA Board. Requests for the
data from the Framingham Heart Study may be
sent to Roby Joehanes (robyjoehanes@hsl.
harvard.edu) or from the link: https://www.ncbi.
nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_
id=phs000724.v6.p10. Requests for the data from
the Biobank-Based Integrative Omics Studies
(BIOS) Consortium (RS, LLS, LL, CODAM and NTR
cohorts) may be sent to Rick Jansen (Ri.
Jansen@ggzingeest.nl) and from the accession
number EGAC00001000277. Requests for the data
from the MARTHA study may be sent to David-
Alexandre Tre´goue¨t (david.tregouet@upmc.fr).
MARTHA Methylation data are already available in
the Array Express database (www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-
3127. Request for the data from the F5L study may
be sent to France Gagnon (france.
gagnon@utoronto.ca).
Funding: Rotterdam Study: The generation and
management of the Illumina 450K methylation
array data (EWAS data) for the Rotterdam Study
was executed by the Human Genotyping Facility of
the Genetic Laboratory of the Department of
Internal Medicine, Erasmus MC, the Netherlands.
The EWAS data was funded by the Genetic
Laboratory of the Department of Internal Medicine,
Erasmus MC, and by the Netherlands Organization
for Scientific Research (NWO; project number
184021007) and made available as a Rainbow
Project (RP3; BIOS) of the Biobanking and
Biomolecular Research Infrastructure Netherlands
(BBMRI-NL). We thank Mr. Michael Verbiest, Ms.
Mila Jhamai, Ms. Sarah Higgins, Mr. Marijn
Verkerk, and Lisette Stolk PhD for their help in
creating the methylation database. The Rotterdam
Study is funded by Erasmus Medical Center and
Erasmus University, Rotterdam, Netherlands
Organization for the Health Research and
Development (ZonMw), the Research Institute for
Diseases in the Elderly (RIDE), the Ministry of
Education, Culture and Science, the Ministry for
Health, Welfare and Sports, the European
Commission (DG XII), and the Municipality of
Rotterdam. The authors are grateful to the study
participants, the staff from the Rotterdam Study
and the participating general practitioners and
pharmacists. Biobank-Based Integrative Omics
Studies (BIOS) Consortium Samples were
contributed by LifeLines (http://lifelines.nl/lifelines-
research/general), the Leiden Longevity Study
genetically defined elevated Hcy eliminate the effects that are possibly caused by measurement
errors, confounding and reverse causality. One of the most consistent genetic variants causing
elevated Hcy is the MTHFR 677C>T (rs1801133), which explains 5.3% variance in Hcy [4].
Furthermore, we recently published 18 variants including MTHFR 677C>T to be robustly
associated with Hcy [5]. The Genetic Risk Score (GRS) of these 18 Hcy-associated variants
explained 5.9% variance in Hcy [5]. In the current study, we used MTHFR 677C>T indepen-
dently and the combined weighted GRS of these 18 variants, to test whether genetically defined
elevated Hcy concentrations are associated with DNA methylation changes in blood cells.
A number of studies [3] have examined the relationship between the MTHFR 677C>T vari-
ant and global DNA methylation in humans. In 5 studies, individuals with the MTHFR 677TT
genotype were compared to those with the MTHFR 677CC genotype [6–10]. Lower global meth-
ylation in blood cells was observed in two studies [6, 7]. The remaining three studies showed no
association in the lymphocyte or colonic tissue. All published studies until now had small sample
sizes of less than 200. To the best of our knowledge, associations of genetically defined Hcy with
site-specific CpG methylation on a genome-wide scale have not been done up to now. In order
to investigate this, we analyzed DNA methylation data measured with the Infinium Illumina
450k arrays, in a large meta-analysis of 9,894 individuals comprising 12 cohorts. We hypothesize
that genetically defined elevated Hcy is associated with altered DNA methylation.
Materials and methods
Study population
All participants provided a written informed consent, and each study was approved at the rele-
vant organizations by their respective ethics review committees [RS, Institutional review board
(Medical Ethics Committee) of the Erasmus Medical Center; LLS, Ethical committee of the
Leiden University Medical Center; LL, Ethics committee of the University Medical Centre
Groningen; NTR, Central Ethics Committee on Research Involving Human Subjects of the
VU University Medical Centre; CODAM, Medical Ethical Committee of the Maastricht Uni-
versity; MARTHA, “Departement sante´ de la direction ge´ne´rale de la recherche et de l’innova-
tion du ministère” (Projects DC: 2008–880 & 09.576); EGCUT; Research Ethics Committee of
the University of Tartu; F5L, Research ethics boards of the University of Toronto and the
Ottawa Hospital Research Institute; FHS, IRB (institutional review board); KORA, Local Eth-
ics Committee; LBC1921, Lothian Research Ethics Committee (Wave 1: LREC/1998/4/183);
LBC1936, Multi-Centre Research Ethics Committee for Scotland (Wave 1: MREC/01/0/56),
and the Lothian Research Ethics Committee (Wave 1: LREC/2003/2/29)].
The analyses comprised of large population with 9,894 participants from 12 cohorts of
European ancestry. Most of the cohorts were part of either the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) consortium [11] and/or Biobank-based Inte-
grative Omics Studies (BIOS) consortium [12]. All participants provided a written informed
consent for the DNA collection and its use for genetic analyses. Each study was approved at
the relevant organizations by their respective ethics review committees. Cohort-specific char-
acteristics are provided in the S1 Text and S1 Table.
MTHFR 677C>T and homocysteine-associated SNPs
18 independent Hcy-associated SNPs from our GWAS meta-analysis [5], were selected to
assess the relationship between mildly elevated Hcy concentrations and genome-wide DNA
methylation. The genotypes of these SNPs were extracted from the genotyping data. Cohort-
specific details of the quality control and the SNP imputation methods are provided in the S2
Table.
Homocysteine-associated variants and DNA methylation
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(http://www.leidenlangleven.nl), the Netherlands
Twin Registry (http://www.tweelingenregister.org),
the Rotterdam studies (http://www.erasmus-
epidemiology.nl/research/ergo.htm), the CODAM
study (http://www.carimmaastricht.nl/), and the
PAN study (http://www.alsonderzoek.nl/). We
thank the participants of all aforementioned
biobanks and acknowledge the contributions of the
investigators to this study, especially Aaron Isaacs,
Rene´ Pool, Marian Beekman, P. Mila Jhamai,
Michael Verbiest, H. Eka D. Suchiman, Marijn
Verkerk, Ruud van der Breggen, Jeroen van Rooij,
Nico Lakenberg, Jan Bot, Patrick Deelen, Irene
Nooren, Martijn Vermaat, Dasha V. Zhernakova,
Rene´ Luijk, Freerk van Dijk, Wibowo Arindrarto,
Szymon M. Kielbasa, and Morris A. Swertz
(S1_File-BIOSconsortiumMembershipList). This
work was carried out on the Dutch national e-
infrastructure with the support of SURF
Cooperative. We acknowledge the support from the
Netherlands CardioVascular Research Initiative (the
Dutch Heart Foundation, Dutch Federation of
University Medical Centres, the Netherlands
Organisation for Health Research and
Development, and the Royal Netherlands Academy
of Sciences) for the GENIUS project “Generating
the best evidence-based pharmaceutical targets for
atherosclerosis” (CVON2011-19). This work was
performed within the framework of the Biobank-
Based Integrative Omics Studies (BIOS)
Consortium funded by BBMRI-NL, a research
infrastructure financed by the Dutch government
(NWO 184.021.007). MARseille THrombosis
Association Study (MARTHA) D.A. was supported
by a PhD grant from the Re´gion Ile de France
(CORDDIM). Statistical analyses of the MARTHA
were performed using the C2BIG computing
cluster, funded by the Re´gion Ile de France, Pierre
and Marie Curie University, and the ICAN Institute
for Cardiometabolism and Nutrition (ANR-10-
IAHU-05). Framingham Heart Study (FHS): The
Framingham Heart Study is funded by National
Institutes of Health contract N01-HC-25195. The
laboratory work for this investigation was funded
by the Division of Intramural Research, National
Heart, Lung, and Blood Institute, National Institutes
of Health. The analytical component of this project
was funded by the Division of Intramural Research,
National Heart, Lung, and Blood Institute Bethesda,
MD. Cooperative health research in the Region of
Augsburg (KORA) The KORA study was initiated
and financed by the Helmholtz Zentrum Mu¨nchen –
German Research Center for Environmental Health,
which is funded by the German Federal Ministry of
Education and Research (BMBF) and by the State
of Bavaria. Furthermore, KORA research has been
supported within the Munich Center of Health
DNA methylation assessment
Whole blood samples were collected from the participants for DNA extraction. The genomic
DNA was bisulfite converted using the Zymo EZ-96 DNA-methylation kit (Zymo Research,
Irvine, CA, USA). Methylation profiling was performed using the Infinium Illumina Human-
Methylation 450k BeadChip arrays (Illumina Inc., San Diego, USA) according to the manufac-
turers’ protocol. Beta values from 0 to 1, which represent the percentage of methylation, were
calculated from the extracted raw methylated (M) and unmethylated (U) probe intensities and
a default alpha (α) of 100. This is defined by the formula of β = M/(M+U+α). Normalization
was performed on these raw beta values using DASEN [13] or SWAN [14] methods. Poor
quality probes were excluded based on the detection p-values mostly>0.01 in>5% of samples.
Cohort-specific data preprocessing methods are provided in the Table 1. Global methylation
levels per sample was calculated by the mean of all CpGs as well as mean according to CpG
islands, shores, shelves or non-coding regions [15].
Statistical analysis
Two models were run independently by each participating study. Firstly, an additive model for
MTHFR 677C>T alone was used to investigate its independent association with genome-wide
DNA methylation in a linear manner. For the MTHFR 677C>T variant, genotypes were coded
as CC = 0, CT = 1 and TT = 2 to study the effect in methylation per MTHFR 677T allele.
In the second analysis, a weighted Genetic Risk Scores (GRS) was constructed from all the
18 Hcy-associated variants to investigate their combined and additive effect on genome-wide
DNA methylation. Weighted GRS were calculated on the basis of their effect sizes [5] and
number of corresponding risk alleles. The product of the two was calculated for each SNP and
then summed up for all SNPs. The GRS was calculated using the equation below, where N is
the number of elevated Hcy causing risk alleles for each SNP (0, 1 or 2 per genotype).
GRS ¼ 0:1583 x Nðrs1801133 : AÞ þ 0:0542 x Nðrs2275565 : GÞ þ 0:0718 x Nðrs234709 : CÞþ
0:0435 x Nðrs4660306 : TÞ þ 0:0453 x Nðrs1801222 : AÞ þ 0:101 x Nðrs12134663 : CÞþ
0:0529 x Nðrs12780845 : AÞ þ 0:056 x Nðrs2851391 : TÞ þ 0:0449 x Nðrs9369898 : AÞþ
0:0422 x Nðrs838133 : AÞ þ 0:0864 x Nðrs7422339 : AÞ þ 0:1242 x Nðrs7130284 : CÞþ
0:0963 x Nðrs154657 : AÞ þ 0:0597 x Nðrs548987 : CÞ þ 0:0395 x Nðrs42648 : GÞþ
0:0512 x Nðrs2251468 : CÞ þ 0:045 x Nðrs957140 : GÞ þ 0:090 x Nðrs12921383 : CÞ
ð1Þ
Both the analyses were based on linear mixed models of lme4 package in R. We also ana-
lyzed the effect of MTHFR 677C>T and GRS on global methylation levels, where we calculated
the overall mean levels per individual as well as categorized the means as per CGI annotations
[15]. The models were adjusted for technical covariates and biological covariates like age, sex
and differential white blood cell (WBC) counts (see S1 Table for details about covariates for
each cohort). The technical covariates were cohort-specific and treated as random effects.
WBC counts were either used as measured counts, or they were imputed based on the House-
man method as implemented in the minfi package [17], or the modified version of the House-
man method (Documentation and R script: https://github.com/mvaniterson/wbccPredictor)
that uses partial least-squares [18] to handle multivariate responses and high-dimensional
covariates and has been previously used [19]. This method from van Iterson used the R pack-
age pls [18] to fit the linear model based on the DNA methylation data, to predict the white
blood cell composition as percentages that sum up to almost 100%. Age and gender were used
as covariates.
Homocysteine-associated variants and DNA methylation
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Meta-analysis
Summary statistics for the two models were obtained from each study. Because of the different
probe exclusions in each cohort [Table 1], we removed probes that were present in4 studies.
We also excluded probes with SNPs at single base extension site, and probes with improper
binding [12], leaving a total of 465,694 probes for the meta-analysis. Meta-analysis was per-
formed using the fixed effect model in METAL [20], with the classical approach that uses effect
size estimates and standard errors as input obtained from the individual study summary statis-
tics for each CpG probe. The output of meta-analysis gave the combined effect size estimates,
standard errors and p-values per probe. These p-values were corrected using the Benjamini
Hochberg method of false discovery rate (FDR), where FDR <0.05 was considered statistically
significant. For the MTHFR 677C>T model, positive effect sizes correspond to percentage
increase in methylation per MTHFR 677T allele. For the GRS model, positive effect sizes corre-
spond to percentage increase in methylation per unit increase in GRS. We also took into
account heterogeneity of the meta-analysis by I2 which was calculated using METAL per probe
and excluded significant probes if I2<40. We also calculated the genomic inflation factor (λ)
[21] to estimate the inflation in test statistics that may be caused by population structure or
other unknown confounding factors. This λ was estimated for the distribution of p-values
using the median method, which is defined as the ratio of the observed median of the test sta-
tistic distribution and the expected median 0.455 [21, 22].
Genomic Regions Enrichment of Annotations Tool (GREAT) was used for annotating
CpGs for nearby genes, that assigns a basal regulatory region to extend up to 5 kb upstream
and 1 kb downstream from its transcription start site and a maximum extension distance up to
1 Mb [23], as defined by UCSC [24]. Furthermore, strength of the instrument or allele score
was calculated using the F-statistics, using the tool, mRnd [25]. We took into account cohort
heterogeneity I2 and excluded significant probes if I2<40.
Identifying cis- and trans-CpG effects
We defined the CpGs as “cis” when the CpG was annotated within 1Mb upstream or down-
stream of the SNP. Trans-CpGs were defined as CpGs that were associated with the SNP, and
were annotated >1Mb apart. We defined the CpGs in the GRS model the same way by
accounting for the bp distance of the CpGs from each of the 18 SNPs. For the significant trans-
CpGs that were 1-5Mb apart from any of the 18 SNPs, we performed a conditional analysis
adjusting for that SNP to investigate whether they were trans-CpGs associated with Hcy GRS
or long range cis-CpGs driven by the nearby SNPs that were part of the GRS. In the conditional
analysis, if the bonferroni corrected p-values were no longer significant, we considered those
trans-CpGs as long-range cis-CpGs. For the significant trans-CpGs that were >5Mb apart
from any of the 18 SNPs, we looked up for their tested individual association with each of the
18 SNPs in our previous trans-CpG mapping analysis [12]. This is to see whether the associa-
tion of these trans-CpGs was Hcy GRS driven or driven by a single SNP that was a part of
GRS. In order to confirm these trans-CpG effects, we performed a similar conditional analysis
by including the respective SNP as a covariate in the model. Both conditional analyses were
performed on a subset of 3,786 samples from 6 cohorts, and the results were compared with
the unconditional analysis in the same subset.
H19/IGF locus
Three Differentially Methylated Regions (DMRs) of IGF2/H19 locus at chromosome 11 have
been reported to be related with homocysteine [26, 27]. We identified seven CpGs on the 450k
array that were underlying the three DMRs of this locus, for their association with MTHFR
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677C>T variant or GRS. Bonferroni method was applied on these 7 CpGs to check for multi-
ple testing.
Enrichment of folate-associated CpGs
We further focused our analysis on the 443 previously identified CPGs, of which methylation
in cord blood of newborns were associated with maternal plasma folate levels [28]. We com-
pared the p-values of these 443 CpGs from the MTHFR 677>T and the GRS results, and com-
pared them to the p-values of 100 random CpGs with 1000 permutations, to check for their
significant enrichment, using the Fisher’s exact test.
Results
Population characteristics
The meta-analysis included 9,894 adults from 12 cohorts. Studies were population-based,
except for the Cohort on Diabetes and Atherosclerosis Maastricht, MARseille THrombosis
Association study and the French-Canadian family study, where individuals were selected
based on mildly increased diabetes mellitus type 2 and cardiovascular risk factors, cases of
venous thrombosis and probands with venous thromboembolism, respectively.
Meta-analysis of MTHFR 677C>T and GRS model
The explained variance in Hcy by MTHFR 677C>T is 5.3% [4] and by GRS is 5.9% [5]. For a
sample size of 9,894, the F-statistics of the additive MTHFR 677C>T and GRS was 554 and
621, respectively. Meta-analysis of 456,694 probes identified 35 cis- [S3 Table] and 1 trans- [S5
Table, Table 2] CpGs for the MTHFR model [Fig 1] and 113 cis- [S4 Table] and 30 trans-
Table 2. Genome-wide trans-CpGs with FDR<0.05; associated with the MTHFR 677C>T model or Genetic Risk Score of 18 Hcy-associated
variants.
CpG N Beta SE P FDR I2 Beta SE P Nearest Genes Chr Bp
MTHFR 677C>T model LOOKUP in GRS model
cg05411165 9894 -0.005 0.001 1.02E-
06
1.40E-
02
0 -0.0095 0.0038 1.16E-
02
ZNF184 (-25414), HIST1H2BL
(+309398)
6 27466334
GRS model LOOKUP in MTHFR
677C>T model
cg12805629 6277 -0.018 0.004 3.15E-
06
1.23E-
02
0 -0.0023 0.0011 3.81E-
02
MRPL55 (+6698), ARF1 (+19954) 2 11565653
cg08586216+ 9894 -0.002 0.001 1.49E-
05
4.89E-
02
37.6 -0.0003 0.0001 4.17E-
02
TULP1 (-131681), FKBP5 (+44391) 6 35612351
cg00620062 9894 0.004 0.001 2.83E-
06
1.12E-
02
0 0.0007 0.0003 3.36E-
03
PTF1A (+6292) 10 23487775
cg00677455* 9334 -0.003 0.001 8.76E-
06
3.09E-
02
0 -0.0004 0.0002 3.63E-
02
CTDSP2 (-269) 12 58241039
cg01259782 6194 0.015 0.004 1.33E-
05
4.52E-
02
0 0.0021 0.0010 2.68E-
02
CRYM (+454) 16 21313973
Beta: Regression coefficients
SE: Standard errors of the regression coefficients
FDR: False discovery rate adjusted P-value, threshold = 0.05
I2: Heterogeneity I2 parameter
*Promoter-associated
+Enhancer-associated, Enhancer annotation from Illumina 450k annotation
https://doi.org/10.1371/journal.pone.0182472.t002
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[Table a in S6 Table, Table a in S7 Table and S8 Table] CpGs for the GRS model [Fig 2]. The λ
was 1.01 for the MTHFR 677C>T SNP and 0.92 for GRS [S1 Fig].
Cis-CpGs
Meta-analysis on 465,694 CpGs of the MTHFR 677C>T variant showed association with 35
cis- CpGs on chromosome 1 with FDR<0.05 [Fig 1, S3 Table]. These cis-CpGs showed a range
from 2.4% increase to 1.7% decrease in methylation per MTHFR 677T allele. The nearest genes
associated with this cis-region included MTHFR itself, AGTRAP, CLCN6, NPPA, NPPB,
PLOD1, MFN2 and TNFRSF8. For the GRS model, we observed 113 cis-CpGs with FDR<0.05
[Fig 2, S4 Table]. Out of the 113, 16 cis-CpGs showed overlap with the MTHFR 677C>T analy-
sis, which involved a smaller region of 238 Kb [Fig 3].
Fig 1. Manhattan plot. Association between MTHFR 677C>T (rs1801133) and genome-wide DNA methylation in 9,894 samples, with 35 cis-
meQTLs at chromosome 1 (black/grey) and 1 trans-meQTL at chromosome 6 (green) with FDR<0.05.
https://doi.org/10.1371/journal.pone.0182472.g001
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Trans-CpGs
For the MTHFR 677C>T model, meta-analysis of 465,694 CpGs identified 1 significant trans-
CpG which was located on chromosome 6 [Fig 1, S5 Table]. This trans-CpG (cg05411165)
showed 1% decrease in methylation per MTHFR T allele. It was annotated near ZNF184
(25414 bp upstream) and HIST1H2BL (309398 bp downstream). For the GRS model, we
observed 30 significant trans-CpGs [Fig 2]. These trans-CpGs showed a range from 5.6%
increase to 5.1% decrease in methylation per 0.1 unit increase in GRS. Of these 30 trans-CpGs,
23 were negatively associated with the GRS model. To assess overlap between two models, we
evaluated association of the trans-CpG of the MTHFR 677 C>T model within the GRS model.
This trans-CpG (cg05411165) showed a 10% decrease in methylation in the GRS model but
was not FDR significant (raw p-value = 0.01).
Critical evaluation of the 30 trans-CpGs of GRS model demonstrated that 14 trans-CpGs
were located in a large region of 3,08 Mb length within chromosome 6. The GRS model con-
sists of 18 SNPs including a SNP on chromosome 6. The 14 trans CpG identified with the GRS
Fig 2. Manhattan plot. Association between GRS of 18 Hcy-associated SNPs and genome-wide DNA methylation in 9,894 samples, with 113 cis-
meQTLs (black/grey) and 30 trans-meQTLs (green), at FDR<0.05.
https://doi.org/10.1371/journal.pone.0182472.g002
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model were at a distance between 1 and 5 Mb away from the Hcy-associated variant rs548987
of the SLC17A3 gene at chromosome 6 [Table a in S6 Table].
Conditional analysis: Chromosome 6 region near rs548987. To investigate whether the
14 trans-CpGs on chromosome 6 near rs548987 were influenced by this variant, we performed
conditional analysis on a subset of 3,786 samples from 6 cohorts. After correction of the model
Fig 3. Regional manhattan plot (chr1: 11824095–12184574). 35 (black) and 16 (green) cis-meQTLs of the MTHFR 677C>T
and GRS model respectively, in 9,894 samples. The overlap involved a small region of 238 kb (green rectangular line).
https://doi.org/10.1371/journal.pone.0182472.g003
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for rs548987 as a covariate, none of the 14 trans-CpGs were significant at a bonferroni thresh-
old of 3.57E-03 [Table b in S6 Table].
Conditional analysis: Influence of SNPs within the GRS model. To further investigate
the remaining 16 trans-CpGs from the 30, whether any of them were driven by a single variant,
rather than the combined effect of the 18 homocysteine-associated variants, we checked the
trans-CpG mapping analysis of the single SNPs using the BIOS dataset [12]. We observed that
7 of the 16 remaining trans-CpGs located >5 Mb from the Hcy-associated variants, were
directly associated with either rs548987 SNP of SLC17A3 gene at chromosome 6, or rs154657
SNP of DPEP1 gene at chromosome 16 [Table a in S7 Table]. After correction for these 7
trans-CpGs by including the respective SNP as a covariate in the model, none of the 7 trans-
CpGs remained significant at a bonferroni threshold of 7.14E-03 [Table b in S7 Table]. After
correction for cis-effects of Hcy-associated SNPs in the GRS model, we identified a remaining
list of 9 Hcy-associated trans-CpGs, 4 of which had substantial heterogeneity I2 [S8 Table].
Overlapping trans-CpG between MTHFR and GRS models
When doing a lookup in the MTHFR 677C>T model for the finally identified 5 trans-CpGs,
all of them showed similar direction of effect, but did not achieve genome-wide significance
(Lowest raw p-value = 3.36E-03) [Table 2].
Trans-CpGs affecting Gene expression
We evaluated whether methylation levels of the observed trans-CpG from the MTHFR
677C>T model and 5 trans-CpGs from the GRS model were associated with expression levels
of the nearby genes, in the BIOS dataset [12]. None of the trans-CpGs was associated with
mRNA expression differences of nearby genes.
H19/IGF2 locus
We specifically focused on the IGF2-H19 region for differential methylation, since methylation
at this locus has repeatedly been linked to the homocysteine metabolism in a number of studies
[29–31]. S4 Fig shows the results of the whole IGF2-H19 region, and the 7 CpGs annotated to
3 DMRs of the IGF2/H19 gene that had previously been reported to be differentially methyl-
ated (DMR0, DMR2, H19-DMR3). Data from our 450k arrays contained 2 CpGs at DMR0, 4
CpGs at DMR2 and 1 CpG at H19-DMR3. None of them showed an association with MTHFR
677C>T or GRS with a Bonferroni cut off of 7.14E-03 [S9 Table, S4 Fig].
Enrichment of previously found folate-associated CpGs
Next we focused on a set of 443 CpGs that were identified to be differentially methylated in
children at birth according to the folate levels in the mothers [28]. We found a highly signifi-
cant enrichment for significant p-values in the MTHFR model in the 443 CpGs as compared
to a random set of other CpGs (>3 times enrichment of significant p-values, enrichment
p = 0.0079). However, we did not find a significant enrichment for the GRS model.
Global DNA methylation changes
In addition to genome-wide DNA methylation changes we analyzed the effect of MTHFR
677C>T and GRS models on overall mean methylation levels. There was no significant associ-
ation between the MTHFR 677C>T or GRS on global methylation overall or mean methyla-
tion of CpG islands, shores, shelves or non-coding regions [Table 3] [15].
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Discussion
This is the first large-scale study to investigate the effect of Hcy-associated SNPs on genome-
wide DNA methylation using the Illumina 450k arrays in 9,894 individuals. The results showed
no widespread trans-effects of the MTHFR 677C>T SNP on DNA methylation, apart from 1
trans-CpG at chromosome 6. The GRS model showed 5 trans-CpGs, after carefully examining
the direct effects of individual SNPs with conditional analyses.
In this current study, we used MTHFR 677C>T independently and the combined weighted
GRS of the 18 Hcy-associated variants [5], to test whether mildly elevated Hcy concentrations
induce DNA methylation changes in blood cells. Our goal was to investigate genetically
defined elevated Hcy on genome-wide DNA methylation. The use of genetic variants is less
sensitive to confounding and bias as compared to classical epidemiological studies [32].
We calculated the strength of our exposure variables: MTHFR 677C>T and GRS using the
F-statistics. For a strong exposure, the value of the F-statistics is expected to be greater than 10
[33]. With our large sample size (n = 9,894) and proportion of variance explained being 5.3 to
5.9%, the F-statistics was 554 and 621 respectively, indicating very high strength and enough
power of our analysis. However, we did not observe widespread trans-effects despite of having
strong additive MTHFR 677C>T and GRS.
We observed a single trans-CpG for the MTHFR 677C>T variant. This CpG is located near
ZNF184 and HIST1H2BL. Both these genes are thought to play a role in transcriptional regula-
tion. For the GRS, we found 30 trans-CpGs associated, 14 of which are spread over a region of
3,08 Mb at chromosome 6. These CpGs were annotated to genes that included ZNF322 and
HIST1H2BJ,HLA-J, HLA-A, HLA-G, but also the proximal region of ZFP57 gene, which was
previously identified as a folate-sensitive region in a genome-wide methylation study of 23
women [34]. However, when we performed a conditional analysis on these 14 CpGs in this
region, by adjusting for the nearby variant rs548987 of the SLC17A3 gene, the effect sizes sig-
nificantly attenuated and the nominal p-values were no more significant. The results indicate
that this region was influenced by the rs548987 SNP of SLC17A3 gene and was not Hcy-
associated.
Table 3. Association of MTHFR 677C>T and Genetic Risk Score on mean global methylation levels.
Methylation N I2 Beta SE P
MTHFR 677C>T
GLOBAL 3,786 0.14 4.00E-06 1.50E-05 0.81
CGI 3,786 0.58 -1.90E-05 4.90E-05 0.70
SHE 3,786 0.59 3.70E-05 5.50E-05 0.50
SHO 3,786 0.14 -9.00E-06 4.80E-05 0.85
NC 3,786 0.61 2.70E-05 4.90E-05 0.57
GRS
GLOBAL 3,786 0.67 -1.30E-05 5.60E-05 0.81
CGI 3,786 0.07 -1.84E-04 1.81E-04 0.31
SHE 3,786 0.00 2.29E-04 2.01E-04 0.25
SHO 3,786 0.52 -1.20E-04 1.76E-04 0.50
NC 3,786 0.07 1.94E-04 1.78E-04 0.28
Beta: Regression coefficients
SE: Standard errors of the regression coefficients
I2: Heterogeneity I2 parameter
CGI = CpG Islands, SHE = CpG Shelves, SHO = CpG Shores, NC = CpGs at Non-Coding regions
https://doi.org/10.1371/journal.pone.0182472.t003
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We finally observed 5 trans-CpGs associated to genetically defined Hcy using the GRS, after
carefully examining the direct effects of individual SNPs with conditional analyses and dis-
carding CpGs that showed substantial cohort heterogeneity I2. A total of 3 CpGs showed hypo-
methylation, one of which was annotated to the FKBP5 gene. FKBP5 encodes for the
FK506-binding protein 51 (FKBP51) whose expression has recently been shown to decrease
DNMT1 activity and thereby decreasing global methylation [35].
Furthermore, when looking at our methylation-expression results [12], none of the 5 trans-
CpGs was associated with mRNA expression differences of nearby genes. The possible expla-
nation for these negative findings could be that these CpG sites might have an effect further
away on trans-genes. Conversely, it has been shown that the methylation-expression correla-
tion in cis are not best predicted using the CpG position alone, but by using specific chromatin
marks [36]. Furthermore, it could also be that these correlations are specific to other tissues,
but not in blood.
We observed that the IGF2-H19 locus did not show association with methylation according
to genetically defined elevated homocysteine. This is in contrast to the previous findings in
mice, where tissue-specific changes in H19 DMR methylation were found in liver, brain and
aorta, and increased expression of H19 was found in aorta [26, 27]. Similar to what we found,
the H19-DMR3 between CBS deficient patients and controls also did not show a significant
difference, in a previous study [29]. Our results show that this imprinted locus is not deregu-
lated by long-term genetically defined mildly elevated homocysteine. However, previously it
was reported that MTHFR 677C>T variant shows changes in DNA methylation in peripheral
blood mononuclear cells, only through an interaction with folate [7]. Hence, further studies
are needed to study the effect of MTHFR 677C>T variant in the presence of blood folate
levels.
We did not see widespread methylation changes associated to mildly elevated plasma Hcy
concentrations. This result is not in line with a number of earlier reports, which have shown
global methylation changes in association with the MTHFR 677C>T variant and Hcy concen-
trations [3]. Previous two studies on this topic have shown contradictory results. There has
been reports that showed a lower circulating global methylation level in individuals with the
MTHFR 677TT genotype [6],[7]. However, there are also a few negative studies that showed
no relation between the MTHFR 677TT genotype and global methylation levels [8–10]. All
these studies had modest sample sizes (upto 300 individuals were studied), and measured
methylation on a global level using the LINE-1 assay, which measures a repetitive sequence, of
which the function is unknown. In contrast, we here studied a genome wide site-specific analy-
sis focused on functional regions of the genome [15]. We here show convincing evidence that
there is no association between the MTHFR 677C>T or GRS on overall methylation levels,
nor is there a relationship between methylation of CpG islands, shores, shelves or non-coding
regions separately, which supports the previous null associations.
Furthermore, in order to test for causal effect in a mendelian randomization study, an
instrument, which is in our case MTHFR 677C>T or GRS, should satisfy the 3 basic assump-
tions [37, 38]. One, the instrument should be associated with the exposure, which is in our
case Hcy. Two, the instrument should not affect the outcome, which is in our case DNA meth-
ylation, except through the exposure Hcy. Three, the instrument should not be associated with
any confounder of the exposure-outcome association. Although assumptions one and two are
satisfied in our case [5], the GRS model might violate assumption three [37, 38].
The GRS model contains a few SNPs which are, in addition to the association with Hcy,
also associated with other traits. For example, the variants near to HNF1A gene have been
associated with a number of other traits [39–44]. This could also be the reason why the results
of the MTHFR 677C>T and GRS models are quite different. Nevertheless, the MTHFR
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677C>T variant explains most of the variation in Hcy, as compared to the other variants in
the GRS model and is therefore a strong instrument to examine the effect of deregulation of
the one-carbon metabolism on methylation.
The relationship between MTHFR 677C>T and DNA methylation is modified by folate lev-
els. Only in individuals with low folate status, the effect of the MTHFR 677TT genotype is seen
[7]. Unfortunately, we were unable to study this interaction, since folate levels were not avail-
able in our study. Another prerequisite to be able to perform MR is that the relationship
between Hcy and methylation is known. The relationship between Hcy and DNA methylation
is only known in studies until now where methylation is measured at a global level. Therefore,
the estimation of the causal effect could not be done. Unfortunately, we also did not have Hcy
data available in all cohorts of this study, and therefore were unable to perform a full mende-
lian randomization study. We rather focused on the association of genetically defined elevated
Hcy levels with DNA methylation.
We did not find widespread differences in methylation related to genetically defined homo-
cysteine levels. The association was not observed in global methylation levels nor in wide-
spread CpGs including the previously known H19/IGF2 locus. There are a number of possible
explanations for this finding. First, it is known that the relationship between MTHFR 677C>T
and DNA methylation is modified by folate levels, as described above. The effect of MTHFR
677C>T is seen in individuals with low folate status [7], which could have masked possible
relationships between the MHTFR variant and methylation. A second possible explanation for
the relative low number of identified CpGs, is that we have studied the wrong tissue. Most
methylation measures are conducted in blood leukocytes as this tissue is readily available.
However, the causal effect of Hcy could be specific to other tissues like liver, heart and brain.
Therefore, the possible effect of mildly elevated Hcy on such specific tissues cannot be
excluded. Third, there is little variation in the one-carbon metabolism in the normal popula-
tion. This metabolism is pivotal to cell survival and function and therefore tidily regulated. It
could be that there is a correlation between homocysteine and more pronounced effects on
methylation when homocysteine levels are more extreme.
Conclusions
We observed 1 trans-CpG (nearest genes ZNF184 and HIST1H2BL) on chromosome 6 associ-
ated with the MTHFR 677C>T variant. The GRS model showed 5 significant trans-CpGs,
which do not overlap with the MTHFR trans-CpG. In conclusion, our results do not show
widespread statistically significant trans-effects of MTHFR and GRS models, and therefore do
not support the hypothesis that genetically defined mildly elevated Hcy concentrations are
associated with widespread methylation changes in leukocytes. More studies with measured
Hcy concentrations are needed to confirm this.
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trans-meQTLs of chromosome 6 with adjustment for the SNP rs548987 of SLC17A3 gene
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Risk Score of 18 Hcy-associated variants in a sample size of 9,894 and were a direct trans-
meQTL of either SNP rs548987 of SLC17A3 gene or rs154657 SNP of DPEP1 gene. (b) Condi-
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